COMP <GO>
BBIO vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
BridgeBio Pharma Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: BBIO 4
— JNJ 9
■ METRIC PARITY
LAST: $74.95 (+5.97%) • MKT CAP: $13.83B
dividend-safety
0.00%
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BBIO VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BBIO | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.80% | 67.90% | +27.90 | BBIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 25.50% | -60.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.23% | 2.97% | -6.20 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 126.30% | 6.00% | +120.30 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 5.59 | -5.14 | JNJ | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 8/9 | -4.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 7.20% | -0.30 | BBIO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.2 | 60.4 | +9.82 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.08 | -0.08 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 33.0x | 23.0x | +10.00 | JNJ | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $13.83B | $662.49B | -$648.66B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BBIO REV | JNJ REV | BBIO GROSS % | JNJ GROSS % | BBIO FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $502.1M | $94.19B | 95.8% | 67.9% | -$447.0M | $19.70B |
| FY 2024 | $221.9M | $88.82B | 98.3% | 69.1% | -$521.7M | $19.84B |
| FY 2023 | $9.3M | $85.16B | 44.0% | 44.0% | -$528.1M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BBIO // BETA 1.00
JNJ // BETA 1.08